title: Oncolytic adenovirus characterization: activity and immune responses.
abstract: Virotherapy in one of the main current applications of recombinant adenoviruses. Oncolytic adenovirus are designed to target tumors, replicate selectively in tumor cells, and elicit immune responses against tumor antigens. Transgene expression in replication-competent oncolytic vectors allows to explore multiple strategies to enhance the potential of virotherapy. In this chapter we describe common in vivo and in vitro techniques used to evaluate the potency and biodistribution of oncolytic viruses. Monitoring immune responses against viral and tumor antigens is crucial as the immune system determines the outcome of virotherapy.
authors.affiliation: Institut Catala d'Oncologia, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
authors.forename: Raul
authors.initials: R
authors.lastname: Gil-Hoyos
authors.forename: Juan
authors.initials: J
authors.lastname: Miguel-Camacho
authors.forename: Ramon
authors.initials: R
authors.lastname: Alemany
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D006224:Cricetinae; D003588:Cytopathogenic Effect, Viral; D003602:Cytotoxicity, Immunologic; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000493:pharmacokinetics; D016679:Genome, Viral; D006801:Humans; D051379:Mice; D050504:Oncolytic Viruses / Q000235:genetics / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019562:Viral Load; D010948:Viral Plaque Assay; D014779:Virus Replication
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral